What changed
Freshness & changelog.
Provenance you can see. Material changes from each monthly refresh are grouped at the top. Below that is every record, most-recently-reviewed first. Review dates show editorial activity; they do not certify that every claim has been verified.
460 records · 0 still seed
New means a record was first added on that date. Updated means an existing record was reviewed on that date.
How we review and score the evidence →
September 2026
September refreshes began on August 27 and continued on September 16–19. The latest release incorporates completed Muse review batches and Astra release checks, corrects three further passages, and simplifies navigation. Full factual verification and worldwide discovery remain unfinished.
Baseline review cutoff 27 Aug 2026 · 194 material changes
19 Sep 2026 · Muse review continuation and simpler navigation
Refresh by GPT-Astra (xhigh)
Contributors: Muse Spark via Muse Code: continuing source comparisons, independent review executions, narrower wording and documented limitations. Runtime details remain recorded as supplied in the review ledgers. · GPT-Astra (xhigh): release integration, targeted primary-source checks and publication. · GPT-Astra (medium): separate pairing audit and medical source spot-check; configured launch settings.
Incorporated the completed review snapshot, including revisions across 257 item and trial records. Checked that the reviewed text matches its evidence records and performed a targeted medical source spot-check. Corrected three additional passages about HDV-insulin lispro, degludec exercise evidence and Control-IQ+ trial comparisons. Fixed review-import date handling and made unknown batch selections fail explicitly. Removed Updates, Review status and Country access as separate public pages; old links redirect to the changelog or the evidence guide. Changelog remains the public change history, with methodological limitations explained on Methodology and source details in individual records.
- This publishes completed work so far; it is not a claim that every factual assertion or programme worldwide has been verified.
- Matching text and paired review records establish traceability, not that every source judgment is correct. Some statements remain scoped, pending or blocked.
- The Astra medical check was a targeted spot-check. Separate AI reviews do not replace independent clinical review.
- Actual review dates are preserved, including work after the original September 17 audit cutoff. The internal register's full completion gate remains unmet.
17 Sep 2026 · Community tools, continuing source verification, and Muse continuation review
Refresh by GPT-Astra (xhigh)
Contributors: Muse Spark via Muse Code: independent review of the Omnipod 6 and SmartGuide batch; primary review of ATG and abatacept, with a separately executed Muse second pass. Exact model version and runtime effort were not independently confirmed. · GPT-Astra (xhigh): release review, targeted source rechecks, corrections and deployment. · GPT-Astra (high): independent medical spot-check and two metadata checks. · GPT-Astra (medium): provenance audit and verification-register history fix. · Parallel AI source reviewers: exact model and effort were not exposed by the worker runtime for this verification continuation.
Added five reader resources — practical side-by-side comparisons, a dated reader digest, country-specific access, a plain-language evidence guide and public review status. Initial coverage includes eight practical device profiles with 45 sourced facts, seven country–item access profiles with 14 sourced fields, and seven digest highlights. Added shared comparison links, visible topic navigation, source scope and dates, and explicit unknown fields. Updated the project map and monthly process to maintain these additional public surfaces. Continued with exact-field source comparisons, independent second passes, corrected older clinical and regulatory claims, and eight further trial records. Corrected five device and therapy records, preserved study and access limitations, and withdrew unsupported Omnipod 6 hardware ratings. Release review caught an older draft overwriting a Dexcom receiver instruction and three review dates; restored the already reviewed text and dates. Added missing primary evidence files and fixed the verification register to retain replaced assertions even when a field or citation position is reused. That release included a review-status page; it was retired on September 19, while the underlying review records remain preserved.
- This is a partial continuation. Whole-record checks, discovery streams and many individual assertions remain incomplete.
- Source-based facts, numerical editorial ratings and manufacturer plans remain distinct. Separate AI passes do not constitute clinical certification.
- The Astra medical review was a high-impact spot-check, not a new claim-by-claim certification of both therapy records.
- Most practical and country-access fields are not yet checked. Country profiles distinguish approval, supply, funding and research; missing information is not evidence that access is absent.
- Digest source dates remain separate from editorial check dates. Sponsor results and future plans retain their study-design, generation and availability limitations.
- Most completed trial units concern registry metadata, not full clinical outcomes. Literature discovery, older assertions, inaccessible full reports and retirement reviews remain unfinished. A pair of AI reviews is not clinician certification, and no worldwide completeness claim is made.
16 Sep 2026 · September follow-up refresh
Refresh by GPT-Astra (xhigh)
Contributors: GPT-Astra (high): Cure and Preventing evidence review · GPT-Astra (high): Living evidence review · GPT-Astra (medium): interface and trial evidence review
Follow-up evidence review with parallel Astra contributors. Added 29 item records and 11 trial records, corrected older evidence and status errors, and connected missing ranking entries with their studies. Added Australian site filtering, shareable filters, insulin-role grouping, clearer evidence summaries and score labels, faster record-specific review pages, and an anonymous About/correction page. Retired Moonshot navigation. Added a repeatable monthly discovery and field-by-field verification process. The homepage now offers direct topic shortcuts and a search box that accepts product and study names. Rebalanced AID default weights to reflect outcomes and daily use (50% glucose/safety, 40% daily experience, 10% access; freedom 20%). Unified exact-score sorting and saved personal weights, added contribution breakdowns and generation-specific caveats, and corrected Diabeloop predecessor claims and Omnipod evidence/specification summaries. Removed numerical scores from four editorial design concepts and separated them from product rankings; named pipeline programmes retain provisional assessments. The homepage has six equal topic cards, with automated insulin delivery after CGMs and clinical trials in the same grid.
- AI-assisted editorial review; independent clinical review remains pending. Model names and settings describe the process, not a guarantee of correctness.
- The baseline cutoff remains August 27. September checks are recorded by scope in the linked review ledger; unchanged historical record dates were not reset simply to make the site look fresh.
- Some full papers, dynamic registries and current local access information could not be independently confirmed. Each review entry records its source depth and limits. Historical release notes describe what the site said at that time and are not current clinical guidance.
- The field-by-field verification register is a new completeness gate and remains pending; record-level review notes and reachable links are not certification that every assertion has passed it. Discovery ledgers retain unresolved candidates rather than claiming an exhaustive index.
27 Aug 2026 · First September evidence pass
Refresh by Grok 4.6 (xhigh)
Historical model attribution. This pass was completed on 27 August and filed under September; its dated entries are preserved.
- Item19 Sep 2026Removed an unsupported exposure-equivalence claim from the tail rationale. The sponsor's secondary maintenance-period hypoglycemia results do not establish a shorter pharmacokinetic tail; the score remains editorial.
- Item19 Sep 2026Replaced blanket exercise-management advice with the scope of the original crossover studies and an individualized-care explanation. Added the repeated-exercise study; no universal dosing adjustment is suggested.
- Item19 Sep 2026Clarified that the type 2 trial's 14-percentage-point time-in-range result is the adjusted treatment difference, not the within-group rise from 48% to 64%. The control group continued usual insulin therapy with CGM.
- Item17 Sep 2026Release review caught and restored a receiver instruction overwritten by an older draft: upload to Clarity before a first G7 15 Day sensor, then update the receiver if prompted. Rechecked the current US guide and restored the FDA page locator. Three editorial review dates were also restored; those earlier source reviews were already published.
- Item17 Sep 2026Corrected the Omnipod 6 pump record against the 29 June 2026 FDA clearance, which covers the software-only algorithm for type 1 diabetes from age 2 and type 2 from 18, not the complete pump system. Withdrew predecessor-based hardware ratings; the programme stays visible without a score until final specifications are published. Launch remains a 2027 manufacturer target.
- Item17 Sep 2026Rechecked SmartGuide against the device manual, both full published studies and current country pages. Corrected calibration, accuracy, wear-survival and adverse-event details; separated retrospective prediction metrics from proven clinical benefit; removed the unsupported lag rating. UK, Australian, German and Middle East access paths are described as advertised.
- Item17 Sep 2026Updated the Omnipod 6 AID record for the FDA algorithm clearance, which supersedes its investigational status without establishing system availability. Headline STRIVE figures keep their 33-person denominator and differing targets; programme dates remain manufacturer plans. Provisional ratings stay explicitly editorial.
- Item17 Sep 2026Rebuilt the low-dose ATG record from the original trial reports: postdiagnosis C-peptide preservation is separated from unproved onset prevention; the terminated two-person stage-2 trial, uncontrolled cohorts and a possible cohort overlap are explicit; dose-versus-placebo signals are not dose equivalence. Removed unsupported affordability and worldwide-stock claims.
- Item17 Sep 2026Rebuilt the abatacept record from the original reports: the 212-person stage-1 trial did not meet its primary endpoint, kept distinct from postdiagnosis C-peptide preservation. Screening versus enrolled ages, the unrelated accidental death and secondary malignancy, and the absence of any T1D label indication are explicit.
- Item17 Sep 2026Rechecked the original FDA order and current manufacturer instructions. Distinguished US and European versions, observed wear survival, meter checks and alert limits. Removed borrowed numerical ratings; the programme remains indexed without a score while detailed device-specific performance evidence remains unavailable in this review. No DKA-prevention benefit is established.
- Item17 Sep 2026Rechecked the original investor presentation and corrected its event date. Preserved design and launch targets as company plans; withdrew numerical ratings based on undisclosed data and unconfirmed specifications. The programme remains visible without a score.
- Trial17 Sep 2026Added the completed three-arm MDI adjunct trial. Distinguished semaglutide or empagliflozin from combined treatment, actual enrollment from planned arm counts, and completion from results; no results are posted.
- Trial17 Sep 2026Added the German before-and-after Predict study. Two consecutive periods are not randomized parallel groups; recruitment, estimated enrollment and the absence of posted results remain explicit.
- Trial17 Sep 2026Added the completed Control-IQ and Lyumjev settings pilot, including young adults as well as adolescents. No results are posted and experimental dosing instructions are not reproduced.
- Trial17 Sep 2026Added the retrospectively registered crossover study. Its detailed protocol compares modes and meal strategies using one 780G despite the title naming two pump models; no outcome results are posted.
- Trial17 Sep 2026Added historical SENCE evidence following the September registry-results posting. Preserved the inconclusive primary endpoint, secondary low-glucose and caregiver findings, older device generation, and unresolved paper–registry discrepancies in participant flow and safety reporting.
- Trial17 Sep 2026Added early insulin-sensing research without implying a noninvasive CGM replacement. Preserved conflicts between the current registry and older consent on the population and enrollment target; no outcomes are posted.
- Trial17 Sep 2026Added the Belgian observational uptake cohort. Age and timing conflicts remain explicit; registry research ages do not establish product eligibility and no results are posted.
- Trial17 Sep 2026Added observational donor-islet quality research. Extracellular-vesicle hypotheses are distinguished from assigned human treatment, and target enrollment and planned outcomes are not presented as results.
- Item17 Sep 2026Rechecked Afrezza against the current US label and original adult trials. Corrected dose-dependent duration, analysis denominators and exercise claims; preserved the failed pediatric noninferiority endpoint alongside approval. Added respiratory, lung-cancer and DKA context, and distinguished country labels and launch reports from actual access. Numerical ratings remain editorial judgments. The FDA label revision is now recorded at its stated month precision, May 2026.
- Item17 Sep 2026Expanded the source review to distinguish measured insulin exposure from modeled flatness in type 2 diabetes, and added the days 2–4 hypoglycemia warning. Preserved the corrected ONWARDS 6 comparison and regional labels; removed unsupported peakless, access and future-programme claims. The full trial paper remains inaccessible, with abstract-only statements identified.
- Item17 Sep 2026Rechecked the original randomized trial and supplement, separating weight outcomes, uncertain glucose outcomes, analysis populations and adverse events. Distinguished T1D glucose-control use from separately licensed obesity treatment, and corrected current label, guidance and phase 3 trial context. Numerical scores remain editorial judgments.
- Trial17 Sep 2026Compared the original ANZCTR record with the trial publication. Distinguished 24 randomized from 22 completing participants, actual study dates, eligibility and prespecified outcomes; short-term results do not establish long-term safety or routine T1D use.
- Trial17 Sep 2026Updated the official registry fields, including recruitment, estimated enrollment and completion, eligibility, outcomes and listed countries. Restored a missing country in the independent check. Estimated dates are not a promise of results publication.
- Trial17 Sep 2026Rechecked the separate phase 3 trial against the official registry, preserving its different estimated enrollment and longer follow-up. Recruitment and study dates are distinguished from results and regulatory approval.
- Item17 Sep 2026Separated standalone Simplera from Simplera Sync. Rechecked original accuracy studies, analysis populations, laboratory comparators, current meter-check instructions, wear limits, regional product configurations and the specified-lot recall. Study and access limitations remain explicit.
- Item17 Sep 2026Corrected the source and population for the pivotal accuracy figures and separated sensor accuracy from whole-system outcomes. Clarified meter checks, transmitter and water limits, specified-lot recall and Australian access changes. A newer dated public-programme notice takes precedence over conflicting older product wording.
- Item17 Sep 2026Corrected water-use wording: the stated pump water rating does not override the manufacturer instruction to remove it before swimming or bathing. This targeted review covers water-use claims and their source; other hardware claims remain separately scoped.
- Item17 Sep 2026Clarified current US sensor choices and possible software updates. Removed the unsupported claim that its lowest target is uniquely lowest among approved pumps. These targeted corrections do not establish comparative superiority or verify the whole record.
- Item17 Sep 2026Removed unsupported claims of sensor superiority and clarified the documented US system configurations. Whole-system glucose outcomes are distinguished from direct analytical sensor accuracy; remaining clinical claims retain their review limits.
- Trial17 Sep 2026Removed an incorrect association with standalone Simplera. The registry names NMX8-AID with DS5/Simplera Sync; its existing NMX8-AID relationship is retained. This relationship correction does not certify every trial field.
- Item17 Sep 2026Added the primary ADA 2026 adult BCG conference report, preserving its subgroup and within-treatment outcome limits. Distinguished the six-person long-term comparison, historical negative trials and separate Yazd findings. Updated registry planning dates and vaccine-use cautions; scores remain editorial.
- Trial17 Sep 2026Added the five-year adult subgroup conference report while retaining the absence of structured registry results. Corrected the distinction between within-arm changes and placebo comparisons, the narrower CGM range and estimated enrollment/completion dates. The full trial report remains needed.
- Item17 Sep 2026Replaced older aggregate accuracy wording with the original pooled study, separating accuracy and wear populations, laboratory comparators, retrospective signal reprocessing and censored sensor survival. Clarified Australian calibration, treatment-confirmation and device-use instructions. Numerical scores remain editorial and need recalibration.
- Item17 Sep 2026Separated the 15 Day label from standard G7 and corrected warm-up, age and receiver instructions. Distinguished sensor-survival estimates from failure rates and kept FDA/journal dataset differences, source-access limits and regional launch uncertainty explicit.
- Item17 Sep 2026Distinguished the shared-sensor Libre 2 Plus pivotal study from direct Libre 3 Plus evidence, including age groups and reference methods. Corrected safety-source dates and meter-confirmation instructions; clarified regional pairing and the announced 1 October Australian standalone subsidy pathway.
- Item17 Sep 2026New. Added the original 14-day Libre 3 separately from Libre 3 Plus. Documented regional transition notices and the advertised German statutory-insurance prescription pathway, with stock unconfirmed. The record is unscored and receives no rank number.
- Item17 Sep 2026Clarified that the older conference announcement alternates between users and sensors, while the later paper reports sensors. The citation note now preserves the unresolved unique-person denominator and does not present observational glucose metrics as an accuracy or randomized-benefit study.
- Trial17 Sep 2026New. Added the published PAINLESS protocol testing Control-IQ and painful diabetic neuropathy. Distinguished screening from randomization targets, study plans from results and conflicting protocol/registry details. Independent registry rechecking remains limited by source access.
- Trial17 Sep 2026New. Added the separate Iranian pediatric BCG report. Distinguished randomized from analyzed participants and preserved conflicting figure values, timelines and missing 18-month control data. The paper does not establish a between-group HbA1c benefit; registry status and formal phase remain unconfirmed.
- Trial17 Sep 2026Made the trial summary consistent with the item review: the assay paper’s abstract and full Results disagree on denominators and subgroup definitions. The discrepancy remains explicit.
- Trial17 Sep 2026Narrowed the predecessor UP421 immune-response statement to fully hypoimmune-modified cells and distinguished study-product adverse events from a possibly procedure-related symptom. SC451 and later follow-up claims retain their separate evidence limits.
- Item17 Sep 2026Expanded the G7 source review: distinguished adult and pediatric accuracy datasets, study funding and estimated lag; corrected version-specific safety, compatibility and regional-access wording. Meter-backup instructions remain explicit. Numerical ratings retain their editorial-calibration limits and unresolved fields remain open.
- Item17 Sep 2026Corrected the cited predecessor trial’s enrollment: 68 randomized and 63 analyzed. This targeted correction does not establish DBLG2-specific efficacy or verify all other claims in the record.
- Item17 Sep 2026Corrected manual-confirmation requirements for correction boluses and the pump’s splash-only water protection. Distinguished current US phone access from Android clearance, adult-only Eversense pairing, interim T1D surveillance and mixed-diabetes sensor data.
- Item17 Sep 2026Corrected the pump’s water limits, phone requirements and button-bolus conditions to match the current manual and commercial guidance. These targeted checks do not verify every remaining statement in the hardware record.
- Item17 Sep 2026Distinguished US Control-IQ v1.5 eligibility from an older international version and the Control-IQ+ successor. Corrected study populations, glucose-variability claims, safety outcomes and t:slim X2 water-use limits; documented version-specific app and Mobi corrections.
- Item17 Sep 2026Corrected randomized versus analyzed populations, real-world follow-up and cohort-specific outcomes. Added the Kaleido/DBLG1 hyperglycemia safety notice and clarified pump-pairing, handset and water-use limits.
- Item17 Sep 2026Corrected randomized versus analyzed populations in older trials, the meaning of the reported 75% comparison, and the failed Protégé primary endpoint. Distinguished original PROTECT outcomes from its selected-population reanalysis and the current US accelerated indication. Full-text access limits remain explicit.
- Item17 Sep 2026Clarified crossover eligibility and safety, within-group insulin-dose changes and US indication scope. Added the August 2026 discontinuation follow-up with its selected-cohort and abstract-only limitations.
- Item17 Sep 2026Clarified the reported sample and subgroup definitions, including conflicting denominators between an original paper’s abstract and full results. Removed an unqualified inference that screening caused a reduction in ketoacidosis.
- Item17 Sep 2026Separated the SC451 development programme from the one-person UP421 study and narrowed the immune-response statement to the fully hypoimmune-modified cells. Clarified the distinction between product-related and procedure-related adverse events. Later follow-up remains qualified by its source depth.
- Trial17 Sep 2026New. Added the ciclosporin/low-dose IL-2 study after comparing ClinicalTrials.gov, CTIS and the public protocol. The registers disagree on recruitment and other details; these conflicts and planned versus evaluable enrollment remain explicit.
- Trial17 Sep 2026New. Added a randomized SmartGuide CGM study from its official registry. Study plans do not establish clinical benefit.
- Trial17 Sep 2026New. Added the MODI insulin-titration study with registered eligibility, endpoints and current recruitment details.
- Trial17 Sep 2026New. Added the DailyDose study; the registry describes planned testing rather than proven treatment effects.
- Trial17 Sep 2026New. Added the completed Control-IQ v1.5 postapproval study, with actual enrollment and completion date. It concerns that version, and no results were posted in the checked registry.
- Trial17 Sep 2026New. Added the GX-01S/LinX postmarket follow-up study. The study listing does not by itself verify country-specific approval or supply.
- Trial17 Sep 2026New. Added a study of barrier approaches for device-related dermatitis, making this everyday device-use burden visible in the trial index.
- Trial17 Sep 2026New. Added PREDIDIA’s capillary autoantibody-testing study with its research eligibility and diagnostic-study limitations.
- Item17 Sep 2026Replaced an earlier conference report with the published August 2026 off-treatment follow-up. Clarified exploratory clinical outcomes, adverse-event denominators and the June-label hypoglycemia warning; separated trial eligibility from approved access. Full follow-up tables remain unverified.
- Trial17 Sep 2026Corrected the description of rescue correction boluses and distinguished the main trial’s insulin from its extension. Added the noninferiority margin and its limits; the full results paper remains only partly accessible.
- Trial17 Sep 2026Corrected sign-ups versus completed screening and the timing of ketoacidosis relative to confirmation. Flagged the correction to the 2026 publication rather than carrying forward unconfirmed cohort figures.
- Trial17 Sep 2026Corrected the listed Dutch sites using the official CTIS record, and separated registry age-band information from full protocol eligibility.
- Trial17 Sep 2026Corrected the jRCT update date and eligibility wording, including duration of insulin dependence and severe-hypoglycemia history.
- Item17 Sep 2026Corrected US and EU decision dates versus announcement dates, strengthened the June-label viral-reactivation warning, and distinguished the original randomized PROTECT results from its newer per-protocol analysis. Safety rating revised from 60 to 45 as an editorial response to the corrected risk rationale.
- Item17 Sep 2026Clarified the day-365 efficacy denominator and severe-hypoglycemia observation window. Corrected the fatal infection attribution to immunosuppressive medication and made the limits of the small, unplanned interim analysis explicit.
- Item17 Sep 2026Corrected study populations, time points and regional compatibility; separated the enhanced 100 mg/dL algorithm’s regulatory simulation evidence from older measured clinical outcomes. Clarified recall instructions and local access.
- Item17 Sep 2026Removed unsupported hardware and launch assertions. Kept manufacturer plans and trial estimates explicitly provisional, and separated successor-system evidence from Omnipod 5 results.
- Item17 Sep 2026Corrected practical specifications and the scope of regional phone, sensor and pharmacy access. Clarified safety-source attribution and study evidence relevant to the pump hardware.
- Trial17 Sep 2026A fresh registry check found the September 16 update now lists active, not recruiting. Updated eligibility and explicitly labeled enrollment and completion dates as estimates.
- Trial17 Sep 2026Corrected the eligible age range to 18–70 and BMI threshold to 25 from the current protocol, and refreshed the source-update date.
- Trial17 Sep 2026Corrected the minimum age to 18 months (1.5 years). The content schema now preserves fractional-year eligibility instead of rounding it to one year.
- Trial17 Sep 2026Corrected the registry phase to Early Phase 1. Narrowed the original immune-response finding to fully hypoimmune-modified cells and distinguished product-related from procedure-related adverse events. The trials interface now distinguishes Early Phase 1 from Phase 1.
- Trial17 Sep 2026Corrected the registered study phase to Phase 2/3 rather than Phase 3.
- Trial17 Sep 2026Clarified that drug phase is not applicable to this pivotal device study; it is not labeled as a pilot.
- Item16 Sep 2026Corrected predecessor-based evidence attribution and removed unexplained score advantages over DBLG1. Shared clinical/feature ratings now use consistent predecessor anchors; phone control retains its documented form-factor benefit. AID default weights were separately rebalanced toward everyday use and access.
- Item16 Sep 2026New. A small Egyptian research protocol proposes turning a participant’s fat-derived cells into insulin-producing cells. No outcomes are posted, and the registry’s estimated completion dates have passed without a status update.
- Item16 Sep 2026New. A discontinued combination programme that preserved more C-peptide during a Phase 2 trial, with benefits diminishing after treatment stopped. It remains historical evidence, not an available T1D therapy.
- Item16 Sep 2026New. An early registered study of engineered red blood cells in recent-onset autoimmune T1D. The public record remains not yet recruiting and has no posted outcomes; current programme activity is uncertain.
- Item16 Sep 2026New. A City of Hope pilot plans to test a person’s own regulatory T cells engineered to target CD6. The registry and hospital list it as not yet enrolling; no T1D outcomes are reported.
- Item16 Sep 2026New. An early dose-escalation study of donor-derived CD7-targeted CAR-T cells in stage 2 or 3 T1D. Nine participants are planned; no outcomes are posted.
- Item16 Sep 2026New. A small investigator-led cell-infusion study in adults with autoimmune T1D and residual insulin secretion. ClinicalTrials.gov lists recruiting, but its update is from July 2025 and no outcomes are posted.
- Item16 Sep 2026New. An antigen-specific immune-tolerance candidate in a recruiting Phase 1b/2a trial. An ADA 2026 abstract reports early tolerability in the first six adults, without a C-peptide efficacy result.
- Item16 Sep 2026New. The IL-17A antibody ixekizumab is being tested for beta-cell preservation after T1D diagnosis. I-DIT is active but no longer recruiting, with no results posted.
- Item16 Sep 2026New. An oral immune-pathway inhibitor tested soon after T1D diagnosis. The latest Phase 2 trial stopped for futility; results posted in August 2026 did not establish beta-cell preservation.
- Item16 Sep 2026New. A regulatory T-cell-directed IL-2 biologic in a recruiting Phase 2 trial for recent-onset T1D. No T1D outcomes are posted; skin-disease results do not establish diabetes benefit.
- Item16 Sep 2026New. A kinase-inhibitor repurposing study asks whether sorafenib can preserve insulin production. The small Phase 2 registry still says not yet recruiting; no T1D results are posted.
- Item16 Sep 2026New. An oral polyamine-pathway inhibitor being studied to reduce beta-cell stress. A small safety trial found an early C-peptide signal; the 74-participant TADPOL study has no posted results.
- Item16 Sep 2026New. Daily GLP-1 therapy studied as an adjunct to insulin in large T1D trials. Modest HbA1c and weight benefits were accompanied by more symptomatic hypoglycemia and hyperglycemia with ketosis; T1D use is off-label.
- Item16 Sep 2026New. An off-label adjunct with modest weight effects but no sustained glucose-control benefit in the large REMOVAL trial. It remains alongside insulin, with tolerability and patient selection limiting its role.
- Item16 Sep 2026New. MicroTech is developing a closed-loop system alongside its Equil pumps and CGM portfolio. Current manufacturer sources establish the program’s existence, but not a launch date, approved configuration or T1D efficacy results.
- Item16 Sep 2026New. Announced successor to CareSens Air, with launch targeted for early 2027. Smaller size, longer wear and a redesigned app are development claims; numerical specifications and clinical performance are not established here.
- Item16 Sep 2026New. An investigational i-SENS CGM identified in an adult T1D accuracy study. The registry still says recruiting despite an elapsed estimated completion date; no results or market authorization are established.
- Item16 Sep 2026New. A 15-day standalone CGM sold in Australia for adults with diabetes. Current manufacturer specifications describe optional calibration and a 30-minute warm-up; the supplied regional manual takes precedence.
- Item16 Sep 2026New. A standalone or Medtrum-pump-integrated CGM with a rechargeable transmitter and up to 14-day sensor wear. It reports every two minutes and offers optional calibration.
- Item16 Sep 2026New. An established CGM family using a separate transmitter and sensor. Current manufacturer specifications describe a one-hour warm-up and optional calibration; model-specific wear life, age labels and local access need confirmation.
- Item16 Sep 2026New. A small standalone CGM with 15-day wear. The current EU manual covers diabetes from age 2, with age-specific insertion sites. Manufacturer accuracy claims are not treated as head-to-head evidence.
- Item16 Sep 2026New. A 15-day standalone CGM sold under regional branding. A 2026 pediatric paper reports 8.89% MARD in 75 per-protocol participants; this does not establish superiority over another CGM or US clearance.
- Item16 Sep 2026New. A smaller iCan CGM family commercialized in China, with 15-day wear and three-minute updates. The international page explicitly excludes sales in the UK and many EU countries; those markets are not marked available.
- Item16 Sep 2026New. An established basal insulin being phased out. Australian and Dutch presentations are scheduled to end in December 2026; the US brand is already on FDA’s discontinued list. Remaining stock must be checked locally.
- Item16 Sep 2026New. Established short-acting human insulin. Its slower meal timing differs from rapid analogues; presentation-specific withdrawals in Australia do not mean all regular human insulin is discontinued worldwide.
- Item16 Sep 2026New. An established wearable patch pump with bolus calculation, temporary basal and extended boluses. MicroTech’s developing closed-loop program is separate; no approved AID functionality is inferred for this pump.
- Trial16 Sep 2026New. Completed phase 2 trial of an immune therapy combined with liraglutide. It found a C-peptide preservation signal during treatment; the development program was subsequently discontinued.
- Trial16 Sep 2026New. A completed 41-person study of oral DFMO, a polyamine-synthesis inhibitor. It met its safety and tolerability endpoint and generated an exploratory C-peptide signal for later testing.
- Item16 Sep 2026Replaced unsupported performance and access assumptions with explicitly speculative assessments; unconfirmed age, grace-period and ketone claims removed.
- Trial16 Sep 2026Corrected the site count to 15 in the September registry update. Protocol age bands are distinct from currently open cohorts, which must be confirmed with the study team.
- Item16 Sep 2026Separated SC451’s preclinical evidence and speculative score from the related UP421 donor-islet human study.
- Item16 Sep 2026Separated the preclinical CTX213 successor from historical CTX211 findings and removed inherited current-access assumptions.
- Item16 Sep 2026Added the overlooked July seven-participant interim update and reconciled it with the older registry estimate. These explant observations do not establish clinical efficacy.
- Item16 Sep 2026Updated the September Omnipod 5 software release and clarified open-source use and support limits.
- Item16 Sep 2026Added the latest stable release and Omnipod 5 support with current documentation.
- Item16 Sep 2026Added US pediatric approval from age six while preserving the failed HbA1c noninferiority finding and country-specific access limits.
- Item16 Sep 2026Corrected the claim that no fingerstick calibration is required: the system requires two initial calibrations.
- Item16 Sep 2026Removed an unsupported advancing-development claim after the program disappeared from Roche’s Phase 2 pipeline.
- Item16 Sep 2026Updated the discontinued platform’s export and account-deletion timeline.
- Item16 Sep 2026Added the iOS application correction and affected version range.
- Item16 Sep 2026Updated the June US label, including the boxed viral-reactivation warning, and clarified age, disease-stage and country-specific access. Added the September PROTECT per-protocol analysis without replacing the original randomized secondary-null findings.
- Item16 Sep 2026Added the September 10 general-population screening consensus. Followed the primary paper’s age windows where an organization’s announcement differed.
- Item16 Sep 2026New. Fully automated option launched September 1 in selected European markets. Availability, age restrictions and the limits of early user evidence are explicit.
- Item16 Sep 2026Corrected the overlooked May 2024 FDA clearance; clearance remains distinct from US commercial availability and from Liberty’s European launch.
- Item16 Sep 2026Added September 14 FDA clearance and the manufacturer’s planned Q1 2027 US launch. The separate 3D Intelligence algorithm remains submitted for review.
- Item16 Sep 2026New. Summarizes randomized adjunct evidence in selected adults with T1D, with obesity/AID criteria, adverse events and off-label status clearly distinguished.
- Item16 Sep 2026New. Adds the approved amylin adjunct and its safety limitations, while showing the discrepancy between FDA discontinued listings and the DailyMed marketing-end date.
- Item16 Sep 2026Separated Lantidra’s 30-person approval program from the 48-person CIT-07 study; corrected safety denominators and added the FDA review’s serious adverse reactions.
- Trial16 Sep 2026Corrected a mislabeled trial: CIT-07 is donor-islet transplantation research, not Lantidra’s registration studies. Preserved the old URL and made the correction explicit.
- Trial16 Sep 2026The September master protocol includes VX-017 safety follow-up and 57 estimated participants. Published VX-880 outcomes remain distinct from unreported VX-017 outcomes and include the serious harms.
- Trial16 Sep 2026Corrected COVALENT-112 to completed after the August 28 update; 37 actual participants and no posted outcome tables.
- Trial16 Sep 2026ASCEND now lists recruiting. Corrected its target enrollment and six-month risk-score endpoint; a surrogate endpoint is not proof of preventing clinical disease.
- Trial16 Sep 2026Corrected a planned enrollment of 150 that had been reported as 150 confirmed participants. No pediatric efficacy result is posted.
- Trial16 Sep 2026Replaced a secondary blog with the primary ADA abstract: 34 randomized, 20 in the primary analysis, and no significant reduction in time below range. This population has pancreatic diabetes after surgery.
- Trial16 Sep 2026Located the primary ADA abstract. Preserved the failed noninferiority result and removed additional figures that could not be corroborated there.
- Trial16 Sep 2026Added the sponsor’s missed composite primary endpoint. Favorable later maintenance analyses remain secondary; the severe-hypoglycemia comparison was not statistically significant.
- Trial16 Sep 2026Corrected the published age range and terminology: participants already had stage 2 T1D. Follow-up of the same trial is not independent replication or permanent prevention.
- Trial16 Sep 2026New. Added the 72-person ADJUST-T1D randomized trial, distinguishing the publication denominator from the broader registry header.
- Trial16 Sep 2026New. Added the crossover trial and its ketosis signal; distinguished the full paper’s placebo-period severe event from safety on semaglutide.
- Trial16 Sep 2026New. Added a missed negative study and August-posted results, with futility, analysis denominators and inconsistent registry units explained.
- Trial16 Sep 2026New September registration: an early pharmacokinetic/gastric-emptying study, with no efficacy results.
- Trial16 Sep 2026New September registration: pregnancy study with no results. The exact registered glucose range is distinguished from standard pregnancy targets.
- Trial16 Sep 2026New September Phase 2/3 registration in recently diagnosed children and adolescents; recruiting, with no results.
- Trial16 Sep 2026New September biobank screening registration; selected genetic-risk participants, not a general public screening service.
- Trial16 Sep 2026New. Added an investigational AMX0035 metabolic trial with a clamp-based insulin-sensitivity endpoint.
- Trial16 Sep 2026New. Added an overlooked completed Phase 1 pump-insulin clamp study. No posted results or clinical-benefit claim.
- Trial16 Sep 2026Current ASK access includes US children and adults and home/Labcorp options; removed an unrelated drug-trial link.
- Trial16 Sep 2026The official ELSA site says screening is paused. Current ages 2–17 are distinguished from the original study cohort.
- Item27 Aug 2026Australia’s PBAC did not recommend PBS listing of Tzield in July 2026. TGA registration stands; subsidy does not. Access score 62 → 58.
- Item27 Aug 2026New. CD154-derived peptide OPT101; Phase 1b results posted 10 August 2026 show a small safety dataset and no C-peptide advantage over placebo.
- Trial27 Aug 2026New. NCT05428943 completed; 24 started, 18 completed; posted mixed-meal C-peptide means were not higher on drug than placebo.
- Trial27 Aug 2026New. Sanofi AL1GN observational cohort (NCT07360080) is recruiting ~1,000 people treated with teplizumab in routine stage-2 care, followed up to 10 years.
- Trial27 Aug 2026New. NOMAD (NCT07758647) will compare open-source vs Control-IQ/Omnipod 5 during unannounced meals; not yet recruiting, estimated start October 2026.
- Trial27 Aug 2026New. NCT05515939 InPen in pediatric T1D is active, not recruiting (n≈34); no results posted; primary completion estimated November 2026.
- Trial27 Aug 2026Registry moved from recruiting to active, not recruiting. The June 2026 12/12 insulin-independence update remains sponsor/conference data, not a posted result, and is still not immunosuppression-free.
- Trial27 Aug 2026Corrected to not-yet-recruiting to match ClinicalTrials.gov. TrialNet’s ASCEND page still says enrolling; both facts are shown.
- Trial27 Aug 2026Completed 7 August 2026 with actual n=59 (was recruiting, estimated 100). No results posted. Adhesive payload study, not insulin-delivery efficacy.
- Trial27 Aug 2026ClinicalTrials.gov still lists active, not recruiting (n=7 follow-up). Vertex discontinued the program in 2025; this record stays terminated.
- Trial27 Aug 2026Now recruiting (NCT07427251), previously not-yet-recruiting. No results.
- Trial27 Aug 2026Summary/results no longer say DIAGNODE-3 is “now being tested” or still enrolling DR3-DQ2 patients. That Phase 3 was terminated for futility.
- Trial27 Aug 2026ClinicalTrials.gov now lists DIAGNODE-3 TERMINATED, whyStopped “Stopped for futility.”, actual n=321, completed 24 June 2026. No results posted.
- Trial27 Aug 2026Live registry: actual enrolment 74 (was estimated 81) and primary completion June 2027 (was December 2027). Still no results.
- Trial27 Aug 2026New. TIRTLE2 (NCT06820281) recruiting Phase 2 clamp study of 6-week tirzepatide 2.5 mg in T1D; estimated n=44. Not a T1D approval.
- Trial27 Aug 2026New. NCT07457580 recruiting retrospective teplizumab managed-access chart review (n≈60). Distinct from prospective AL1GN.
- Trial27 Aug 2026New. INNODIA DETECT (NCT07118098) recruiting European relatives/friends autoantibody screen; estimated n=30,000.
- Item27 Aug 2026New. Queensland Phase 1 antigen-specific liposome (proinsulin peptide plus calcitriol). Registry recruiting; Part A complete, Part B open; no efficacy results.
- Trial27 Aug 2026New. ACTRN12624001043527 recruiting; target n=36, accrual 27 as of 2 July 2026. Safety primary; mixed-meal C-peptide is a Part B secondary, not a posted result.
- Trial27 Aug 2026New. NCT07594145 not-yet-recruiting T1D Phase 2 of finerenone or sotagliflozin for early kidney/heart-risk markers (n≈57). Type 2 excluded.
- Trial27 Aug 2026New. NCT07087795 active, not recruiting Phase 1 of zalfermin ± semaglutide in T1D (n≈96). No results. NASH discontinuation is not a T1D result.
- Trial27 Aug 2026New. NCT05777330 recruiting Belgian CGM/OGTT staging study in autoantibody-positive people aged 5–39 (n≈75). No results.
- Trial27 Aug 2026New. NCT06908057 ACCESS-T1D Florida relatives/autoimmune screen; active, not recruiting; actual n=115. No results posted.
- Item27 Aug 2026New. Japanese first-in-human TUFF-IPC (autologous adipose-derived insulin-producing cells); jRCT2063250055 recruiting, target n=3. No results.
- Trial27 Aug 2026New. jRCT2063250055 recruiting Phase 1/2a in Tokushima; safety to day 60 is primary. Fasting C-peptide ≥0.3 ng/mL (0.1 nmol/L) is protocol engraftment, not a posted result.
- Item27 Aug 2026New. LUMC autologous tolerogenic dendritic-cell programme; distinct from City of Hope PIpepTolDC. Phase 1b recruiting; first-patient news is n=1.
- Trial27 Aug 2026New. EUCT 2023-508558-25-01 recruiting in the Netherlands; target n=10. No posted C-peptide results.
- Trial27 Aug 2026Live registry ages are 1–34 (was written 8–34). Still recruiting, n=10 estimated; no results.
- Item27 Aug 2026Added FDA Class II recall number Z-2574-2026 for the two stolen/resold G7 lots already described. Not a G7 design defect.
- Item27 Aug 2026FDA De Novo authorization 25 August 2026 for the 10-day dual glucose-ketone sensor, ages 2+. Authorization is not a US or EU launch.
- Item27 Aug 2026NICE discontinued its type 1 appraisal on 30 July 2026 after Lilly said it was not pursuing a UK type 1 licence. CHMP’s type-2-only Onswik opinion is still not a marketing authorisation.
- Trial27 Aug 2026Live registry is ages 13–21 at Wayne State (was written 2–17). Still active, not recruiting; no results.
- Trial27 Aug 2026ISRCTN target enrolment is now 50,000 (was 20,000); estimated completion 31 August 2029. Still recruiting. 17,283 remains an interim count.
- Item27 Aug 2026New. Immunocore IMC-S118AI (pre-proinsulin × PD-1). First-in-human registered; no human efficacy.
- Trial27 Aug 2026New. NCT07493122 not yet recruiting on ClinicalTrials.gov; EU CTIS authorised July 2026. No results.
- Trial27 Aug 2026New. NCT06964087 recruiting subcutaneous OPT101 Phase 2 (n≈72). Not a posted C-peptide result.
- Trial27 Aug 2026New. NCT07051564 / ChiCTR2600116392 recruiting Chinese universal CAR-T/NKT in T1D. Safety first; no results.
- Trial27 Aug 2026New. NCT06435156 recruiting UK Phase 2 of sotagliflozin in T1D with heart failure (n≈320). Type 2 HF data do not score this record.
- Trial27 Aug 2026New. NCT06217302 recruiting T1D CKD Phase 3 of sotagliflozin (n≈150). Not a Type 1 licence.
- Item27 Aug 2026Italy’s first national wave is 5- and 6-year-olds at vaccination visits, not every child aged 1–17. Reach 92 → 70; access 80 → 72.
- Item27 Aug 2026Phase 1 enrollment is complete (actual n=6). Follow-up continues; no results posted.
- Item27 Aug 2026CATT1 is ACTIVE_NOT_RECRUITING on the live registry. Primary completion estimated April 2027 — not the older H2 2026 topline.
- Item27 Aug 2026Libre Duo 10 Day is FDA-authorized (25 Aug 2026), so the ketone sensor exists. No AID algorithm yet acts on the ketone channel. Authorization ≠ launch.
- Item27 Aug 2026MiniMed began commercially shipping Flex with Abbott Instinct in the US on 17 August 2026. Shipping is not Flex-specific outcome data.
- Item27 Aug 2026Instinct now ships with MiniMed Flex in the US (17 August 2026), in addition to 780G and MiniMed Go.
- Item27 Aug 2026Flex + Instinct US shipping began 17 August 2026; Instinct is no longer a summer promise on this AID record.
- Item27 Aug 2026TrialNet stage-1 golimumab substudy (NCT07683026) is still not-yet-recruiting after its estimated 8 August 2026 start.
- Trial27 Aug 2026Estimated start 8 August 2026 has passed; live registry remains not-yet-recruiting (last update 6 July 2026).
- Trial27 Aug 2026Enrollment complete, actual n=6. Follow-up estimated through 15 December 2026. No results posted.
17 Sep 2026
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialNew
- TrialNew
- ItemUpdated
- TrialNew
- TrialNew
- TrialNew
- TrialNew
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialNew
- ItemNew
- ItemUpdated
- TrialUpdated
- TrialNew
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialNew
- TrialNew
- TrialNew
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialNew
- TrialNew
- ItemUpdated
- TrialUpdated
- TrialNew
- TrialNew
- ItemUpdated
- TrialNew
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- ItemUpdated
16 Sep 2026
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemNew
- ItemNew
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemNew
- TrialNew
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemNew
- ItemNew
- ItemNew
- ItemNew
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemNew
- ItemNew
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemNew
- TrialNew
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- TrialNew
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemNew
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemNew
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemNew
- TrialNew
- ItemUpdated
- ItemNew
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemNew
- ItemNew
- TrialNew
- ItemNew
- ItemNew
- ItemNew
- ItemNew
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialNew
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemNew
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemNew
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemNew
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemNew
- ItemNew
- ItemUpdated
- ItemUpdated
- ItemNew
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialNew
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
27 Aug 2026
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialNew
- ItemUpdated
- TrialUpdated
- ItemNew
- TrialNew
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemNew
- TrialNew
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemNew
- ItemUpdated
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialNew
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemNew
- TrialNew
- ItemUpdated
- ItemUpdated
- ItemUpdated
- ItemUpdated
- TrialNew
- TrialUpdated
- TrialNew
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- TrialNew
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialNew
- TrialNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemNew
- TrialUpdated
- TrialUpdated
- TrialUpdated
- ItemUpdated
- ItemUpdated
- TrialUpdated
- TrialUpdated
This view is generated from each record’s review date. As new evidence is ingested and rankings re-scored, updated records rise to the top. How it works →